Convexia, a pharmaceutical company that uses AI to buy drugs, run clinical trials, and sell the drugs, has been launched. Founders Rahul Vijayan and Ayaan Parikh — who have previously created and exited three startups together — have referred to Convexia as an “AI-maximalist pharma company.”
The founders claim that pharma is the “most bloated, antiquated trillion-dollar industry on the planet,” with life-saving drugs being overlooked, abandoned, or shelved because “diligence is still done by hand.” They believe Convexia can help solve this problem through its AI agents.
READ: Y Combinator-backed startup Golpo reinvents AI video generation (July 30, 2025)
Convexia’s AI agents can autonomously handle sourcing and find hidden early-stage drugs from around the world. It also uses leading computational biology tools to evaluate drug viability and perform scientific diligence. The AI agents also perform market analysis, analyzing model market size, competition, and IP positioning.
Convexia’s AI agents can also perform clinical operations including simulation of trials, flagging CMC issues, and discovering CROs. It can also play a role in business development by matching each drug to the right user.
According to the Convexia website, it works as an “end-to-end AI stack that replaces months of manual diligence with fast execution.” Operations begin with the asset discovery agent scanning the globe for overlooked drug assets — from preclinical biotech to abandoned pharma IP. This is followed by the company’s 50 custom-tuned models assessing binding, toxicity, ADME/PK, immunogenicity, and mechanistic fit. Then, there is a specialist human review, which involves PhDs with domain expertise reviewing each asset’s biology, risks, and translatability before approving it for development.
READ: CopyCat debuts as new AI-powered robotic automation platform (July 25, 2025)
The market insight agent then ranks assets based on various market-shaping factors. The operational risk agent then scores execution risks before trials start. This is followed by a business development agent helping package and pitch to pharma. Then, there’s a final call where a live roundtable of experts make the final call.
Convexia claims its AI is different because it is “built for real-world drug development, not just to say we use AI.”
Read more on The American Bazaar
